Uncategorized
Targeted Protein Degradation Market PROTAC Segment is Expected to Highest Growth Rate During 2024-2031 | Revealed by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Targeted Protein Degradation Market“- Distribution by Type of Degrader (SERD, PROTAC and Molecular Glue), Target Indication (Breast Cancer and Multiple Myeloma), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031.”
The Targeted Protein Degradation Market is estimated to reach over USD 2.65 Bn by 2031, exhibiting a CAGR of 26.3% during the forecast period.
Targeted protein degradation (TPD) seeks to completely remove specific proteins from the cell, rather than merely inhibiting their activity. This approach can potentially provide more effective and sustained treatment outcomes for various diseases by thoroughly eliminating disease-causing proteins. By leveraging the cell’s natural degradation pathways, TPD can address issues that traditional therapies cannot, such as drug resistance and incomplete inhibition. Consequently, this innovative strategy holds significant promise for advancing the treatment of conditions like cancer, neurodegenerative diseases, and infectious diseases, offering new hope for patients with previously intractable conditions.
Targeted protein degradation (TPD) seeks to completely remove specific proteins from the cell, rather than merely inhibiting their activity. This approach can potentially provide more effective and sustained treatment outcomes for various diseases by thoroughly eliminating disease-causing proteins. By leveraging the cell’s natural degradation pathways, TPD can address issues that traditional therapies cannot, such as drug resistance and incomplete inhibition. Improved techniques in drug delivery, high-throughput screening, and protein engineering are enhancing the efficacy and specificity of TPD therapies.
Download Free Sample and ToC of the Report: https://www.insightaceanalytic.com/request-sample/2530
List of Prominent Players in the Targeted Protein Degradation Market:
Arvinas
Bristol-Myers Squibb
C4 Therapeutics
Loxo Oncology
Olema Oncology
Radius Health
AstraZeneca
Roche
BeiGene
InnoCare Pharma
Kangpu Biopharmaceuticals
Kintor Pharmaceuticals
Medivir
Monte Rosa Therapeutics
Ranok Therapeutics
Sanofi
Zentalis Pharmaceuticals
Eisai Therapeutics
Targeted Protein Degradation Market Report Scope:
Report Attribute
Specifications
Market Size Value In 2023
USD 0.42 Bn
Revenue Forecast In 2031
USD 2.65 Bn
Growth Rate CAGR
CAGR of 26.3% from 2024 to 2031
Quantitative Units
Representation of revenue in US$ Bn and CAGR from 2024 to 2031
Historic Year
2019 to 2023
Forecast Year
2024-2031
Report Coverage
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered
By Distribution by Type of Degrader, Target Indication
Regional Scope
North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia
Order 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2530
Market Dynamics:
Drivers:
The promising potential of TPD to transform disease treatment is attracting significant interest and investment from venture capitalists and pharmaceutical companies. Positive outcomes from ongoing research and clinical trials are boosting confidence in TPD therapies, accelerating their development. Additionally, partnerships between pharmaceutical companies, biotech firms, and academic institutions are fostering innovation and expanding the reach of TPD research and applications. The global increase in diseases such as cancer and neurodegenerative disorders is creating a demand for innovative therapies, making TPD a valuable approach.
Challenges:
Developing PROTACs and other TPD molecules is technically complex, requiring precise design to ensure efficacy and selectivity. Potential off-target effects and toxicity are significant concerns, necessitating thorough evaluation in preclinical and clinical trials. Additionally, high research and development costs, along with the need for extensive clinical trials, can be prohibitive for some companies.
Regional Trends:
There’s a growing focus on personalized medicine in North America, with an emphasis on developing targeted therapies for specific patient populations. TPD aligns well with this trend, offering the potential for more precise and effective treatments. The region boasts a well-established and well-funded pharmaceutical industry with a strong track record of innovation in drug discovery. These companies have the resources and expertise to invest heavily in TPD research and development, propelling the market forward.
Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2530
Recent Developments:
In April 2024, Arvinas, Inc., announced that it has signed a strategic license agreement with Novartis for the global development and commercialization of ARV-766, Arvinas’ second-generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. is a clinical-stage biotechnology company developing a new class of drugs based on targeted protein degradation. An asset purchase agreement for the sale of Arvinas’ preclinical AR-V7 program to Novartis is also a part of the transaction.
In September 2023, Bristol Myers Squibb is hosting a Research and Development (R&D) Day in New York to discuss the company’s R&D capabilities and strategy and provide information about its strong pipeline that supports sustainable long-term growth. The company’s leadership team will also showcase its improved R&D framework and unique research platforms, which are anticipated to provide exceptional productivity that produces top-notch early-stage candidates and noticeably shortens R&D timelines.
Segmentation of Targeted Protein Degradation Market.
By Type of Degrader
SERD
PROTAC
Molecular Glue
By Target Indication
Breast Cancer
Multiple Myeloma
By Region
North America–
The US
Canada
Mexico
Europe–
Germany
The UK
France
Italy
Spain
Rest of Europe
Asia-Pacific–
China
Japan
India
South Korea
Southeast Asia
Rest of Asia Pacific
Latin America–
Brazil
Argentina
Rest of Latin America
Middle East & Africa–
GCC Countries
South Africa
Rest of the Middle East and Africa
For More Customization @ https://www.insightaceanalytic.com/customisation/2530
Why should buy this report:
To receive a comprehensive analysis of the prospects for global Targeted Protein Degradation market
To receive industry overview and future trends of global Targeted Protein Degradation market
To analyze the Targeted Protein Degradation market drivers and challenges
To get information on the Targeted Protein Degradation market size value (US$ Mn) forecast till 2031
Major Investments, Mergers & Acquisition in global Targeted Protein Degradation industry
Other Related Reports Published by InsightAce Analytic:
SERD Therapeutics Market
Molecular Glue Degrader Market
Protein Design and Engineering Market
Check Our Satisfied Clients Portfolio @ https://www.insightaceanalytic.com/our-clients
The post Targeted Protein Degradation Market PROTAC Segment is Expected to Highest Growth Rate During 2024-2031 | Revealed by InsightAce Analytic Pvt. Ltd. appeared first on HIPTHER Alerts.